MA43862A - Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock - Google Patents

Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock

Info

Publication number
MA43862A
MA43862A MA043862A MA43862A MA43862A MA 43862 A MA43862 A MA 43862A MA 043862 A MA043862 A MA 043862A MA 43862 A MA43862 A MA 43862A MA 43862 A MA43862 A MA 43862A
Authority
MA
Morocco
Prior art keywords
related compounds
rock inhibitors
salicylamides
spiroheptane
spiroheptane salicylamides
Prior art date
Application number
MA043862A
Other languages
English (en)
Inventor
Indawati Delucca
Andrew K Dilger
Peter W Glunz
Vladimir Ladziata
Michael J Orwat
Kumar Balashanmuga Pabbisetty
Manoranjan Panda
Donald J P Pinto
Scott A Shaw
Ii Leon M Smith
Wu Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA43862A publication Critical patent/MA43862A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA043862A 2016-01-13 2017-01-13 Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock MA43862A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13

Publications (1)

Publication Number Publication Date
MA43862A true MA43862A (fr) 2021-06-02

Family

ID=57907009

Family Applications (2)

Application Number Title Priority Date Filing Date
MA043862A MA43862A (fr) 2016-01-13 2017-01-13 Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA055633A MA55633A (fr) 2016-01-13 2017-01-13 Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055633A MA55633A (fr) 2016-01-13 2017-01-13 Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock

Country Status (29)

Country Link
US (2) US10611776B2 (fr)
EP (2) EP3954681A1 (fr)
JP (2) JP6976953B2 (fr)
KR (1) KR102725741B1 (fr)
CN (1) CN108699038B (fr)
AR (1) AR107354A1 (fr)
AU (2) AU2017206820B2 (fr)
BR (1) BR112018013780B1 (fr)
CA (1) CA3010900A1 (fr)
CL (1) CL2018001899A1 (fr)
CO (1) CO2018008173A2 (fr)
CY (1) CY1124858T1 (fr)
EA (1) EA036172B1 (fr)
ES (1) ES2898698T3 (fr)
HR (1) HRP20211888T1 (fr)
HU (1) HUE057455T2 (fr)
IL (1) IL260448B (fr)
LT (1) LT3402790T (fr)
MA (2) MA43862A (fr)
MX (2) MX382434B (fr)
PL (1) PL3402790T3 (fr)
PT (1) PT3402790T (fr)
RS (1) RS62690B1 (fr)
SG (1) SG11201805927YA (fr)
SI (1) SI3402790T1 (fr)
SM (1) SMT202100660T1 (fr)
TW (1) TWI730032B (fr)
UY (1) UY37073A (fr)
WO (1) WO2017123860A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103990A1 (es) 2015-01-09 2017-06-21 Bristol Myers Squibb Co Ureas cíclicas como inhibidoras de rock
US10112929B2 (en) 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
PL3722284T3 (pl) 2016-01-13 2025-03-31 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
AR107354A1 (es) * 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
LT3402782T (lt) 2016-01-13 2020-10-12 Grünenthal GmbH 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PL3402784T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
CN109153663B (zh) 2016-05-27 2021-08-13 百时美施贵宝公司 作为rock抑制剂的三唑酮类化合物和四唑酮类化合物
ES2829550T3 (es) 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
JP7113810B2 (ja) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロラクタム
ES2814325T3 (es) 2016-07-07 2021-03-26 Bristol Myers Squibb Co Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
WO2018102325A1 (fr) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Inhibiteurs de rho kinase tricyclique
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
EP3652167B1 (fr) * 2017-07-12 2021-06-02 Bristol-Myers Squibb Company Spiroheptanyl hydantoïnes utilisés en tant qu'inhibiteurs de rock
TW201908293A (zh) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
WO2019014303A1 (fr) * 2017-07-12 2019-01-17 Bristol-Myers Squibb Company Inhibiteurs aminohétérocycliques à cinq chaînons et aminohétérocycliques bicycliques à 5,6 ou 6,6 chaînons de rock pour le traitement de l'insuffisance cardiaque
CN110869360B (zh) 2017-07-12 2023-12-15 百时美施贵宝公司 作为rock抑制剂的苯乙酰胺类
WO2019060365A1 (fr) * 2017-09-20 2019-03-28 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
US11192891B2 (en) 2017-11-03 2021-12-07 Bristol-Myers Squibb Company Diazaspiro ROCK inhibitors
KR102815312B1 (ko) * 2018-04-17 2025-05-30 템페스트 테라퓨틱스, 인크. 비시클릭 카르복스아미드 및 그의 사용 방법
AU2022385051A1 (en) 2021-11-11 2024-06-20 Actualeyes Inc. Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
JP7797234B2 (ja) 2022-02-18 2026-01-13 キヤノン株式会社 保持装置、リソグラフィ装置、および物品製造方法
WO2024013736A1 (fr) * 2022-07-12 2024-01-18 Adama Makhteshim Ltd. Procédé de préparation de benzamides substitués
WO2024229439A2 (fr) * 2023-05-03 2024-11-07 The University Of Chicago Inhibiteurs de structures actives médiées par nsun1 et nsun2
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025247783A1 (fr) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Composés dihydro-benzoxazinone à action pesticide
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007142323A1 (ja) * 2006-06-08 2009-10-29 宇部興産株式会社 側鎖にスピロ環構造を有する新規インダゾール誘導体
CA2664335C (fr) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Inhibiteurs de la rho-kinase
JP5405314B2 (ja) * 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
RU2010131010A (ru) * 2007-12-26 2012-02-10 Санофи-Авентис (Fr) Способ получения 6-замещенных-1-(2н)-изохинолинонов
PE20140913A1 (es) 2010-11-15 2014-08-22 Abbvie Inc Inhibidores de nampt y rock
US9221767B2 (en) 2013-01-18 2015-12-29 Bristol-Myers Squibb Company Substituted phthalazinones as rock inhibitors
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
AR103990A1 (es) 2015-01-09 2017-06-21 Bristol Myers Squibb Co Ureas cíclicas como inhibidoras de rock
US10112929B2 (en) 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
AR107354A1 (es) * 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
CN109153663B (zh) 2016-05-27 2021-08-13 百时美施贵宝公司 作为rock抑制剂的三唑酮类化合物和四唑酮类化合物
JP7113810B2 (ja) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロラクタム
ES2814325T3 (es) 2016-07-07 2021-03-26 Bristol Myers Squibb Co Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
ES2829550T3 (es) 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
WO2018102325A1 (fr) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Inhibiteurs de rho kinase tricyclique

Also Published As

Publication number Publication date
LT3402790T (lt) 2021-12-10
MX382434B (es) 2025-03-13
SG11201805927YA (en) 2018-08-30
US20200131200A1 (en) 2020-04-30
CN108699038B (zh) 2021-04-16
CA3010900A1 (fr) 2017-07-20
US10611776B2 (en) 2020-04-07
EP3402790A1 (fr) 2018-11-21
JP7268116B2 (ja) 2023-05-02
PT3402790T (pt) 2021-11-22
PL3402790T3 (pl) 2022-01-24
US10829501B2 (en) 2020-11-10
KR102725741B1 (ko) 2024-11-01
BR112018013780A2 (pt) 2018-12-11
JP2019509978A (ja) 2019-04-11
CN108699038A (zh) 2018-10-23
JP2022024019A (ja) 2022-02-08
ES2898698T3 (es) 2022-03-08
EP3402790B1 (fr) 2021-10-06
TW201726619A (zh) 2017-08-01
HUE057455T2 (hu) 2022-05-28
MA55633A (fr) 2022-02-16
AU2021221872A1 (en) 2021-09-23
RS62690B1 (sr) 2021-12-31
WO2017123860A1 (fr) 2017-07-20
AR107354A1 (es) 2018-04-18
SMT202100660T1 (it) 2022-01-10
AU2017206820A1 (en) 2018-08-23
AU2017206820B2 (en) 2021-06-17
UY37073A (es) 2017-07-31
CY1124858T1 (el) 2022-11-25
KR20180097749A (ko) 2018-08-31
US20190016735A1 (en) 2019-01-17
EP3954681A1 (fr) 2022-02-16
MX2018008219A (es) 2018-09-07
IL260448B (en) 2020-09-30
CO2018008173A2 (es) 2018-08-21
EA201891557A1 (ru) 2019-01-31
EA036172B1 (ru) 2020-10-09
MX2021005311A (es) 2021-06-23
CL2018001899A1 (es) 2018-11-09
TWI730032B (zh) 2021-06-11
JP6976953B2 (ja) 2021-12-08
BR112018013780B1 (pt) 2023-12-19
HRP20211888T1 (hr) 2022-03-04
SI3402790T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp